
    
      This is an open label, single territory, multi-centre study in subjects with pulmonary
      arterial.

      hypertension (PAH). Subjects were treatment na√Øve or receiving an approved endothelin
      receptor antagonist (ERA) and / or phosphodiesterase (PDE)-5 inhibitor for at least 60 days
      prior to screening and maintained on a stable dose for at least 30 days.
    
  